trial

Once-Daily Asenapine for Schizophrenia

NCTId NCT01549041
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 30 (actual)
Sponsored by Duke University
Primary completion 2013-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
30 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2012-04
Primary completion
2013-04
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Asenapine

Sponsors

Duke UniversityLead Sponsor
Merck Sharp & Dohme LLCCollaborator

Investigators

1
John Beyer, MDPrincipal Investigator

Sites

1 total
Butner, United States

Facts & assertions

4 sourced
Enrollment
30
Phase
PHASE4
Primary Completion Date
2013-04
Status
COMPLETED
relationships
The graph out of here
drug
Asenapine
drug
lead_sponsor
Duke University
company
collaborator
Merck Sharp & Dohme LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
John Beyer, MD
person